BofA analyst Jason Gerberry raised the firm’s price target on Fractyl Health (GUTS) to $5 from $4 and keeps a Buy rating on the shares. The firm increased the probability of success for Revita to 55% from 20% following the Remain-1 data. The the midpoint analysis of Revita in weight maintenance were better than expected, the analyst tells investors in a research note. The firm says Revita-treated patients lost an additional 2.5% body weight versus sham regaining 10% of body weight at three months and there were no safety red flags.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GUTS:
- Promising Potential of Fractyl Health’s Revita Therapy Drives Buy Rating
- Fractyl Health price target lowered to $8 from $9 at H.C. Wainwright
- Fractyl Health Announces $60M Stock Offering Pricing
- Fractyl Health Reveals Promising REMAIN-1 Study Results
- Fractyl Health prices 60M shares at $1.00 in underwritten offering